期刊文献+

海洋交替假单胞菌QD1-2抗肿瘤活性辅酶Q衍生物的分离与结构鉴定

Isolation and Structure Elucidation of An Antitumor Ubiquinone Derivative from the Marine Bacterium Pseudoalteromonas rubra QD1-2
下载PDF
导出
摘要 海洋交替假单胞菌(Pseudoalteromonas rubra QD1-2)是从青岛海域分离筛选出的一株具有抗肿瘤活性的菌株。为了明确海洋交替假单胞菌(Pseudoalteromonas rubra QD1-2)的抗肿瘤活性成分和结构,利用大孔树脂柱层析、半制备HPLC等分离方法,首次从菌株QD1-2发酵液中分离到了一个单体化合物。通过高分辨率质谱、一维和二维核磁共振波谱等现代波谱技术进行结构鉴定,经测定,分子量为320,分子式为C18H24O5,为辅酶Q2衍生物。最后利用MTT法进行抗肿瘤活性测试,显示了较强的抗肿瘤活性。这一结果揭示了海洋交替假单胞菌产生新颖抗肿瘤化合物巨大的潜力,该属为寻找新型抗肿瘤天然化合物提供了新的来源。 A marine bacterium,Pseudoalteromonas rubra QD1-2,was isolated from the Qingdao sea in China. The crude culture of QD1-2 was highly active against human tmnor cells. In order to confirm chemical structure of the anfitumor compound ,The crude metabolites of QD1-2 was isolated and purified by using column chromatography with Diaion HP20 maeroporous resin and then purified it by preparative HPLC. The chemical structure of the active compound finally ob- tained was achieved with spectroscopy methods ,including high resolution mass spectrometry andlD and 2D nuclear mag- netic resonance. According to the analysis results ,we identified the active compound as a ubiquinone derivative with the molecular weight of 320, the molecular formula C18H24O5. Finally antitumor activity was tested by the MTr method, showing very strong. The results revealed the huge potential of discovering novel antitumor compounds from Pseudoaltero- monas, providing new sources for antitumor natural compounds.
出处 《天然产物研究与开发》 CAS CSCD 北大核心 2014年第7期1021-1025,共5页 Natural Product Research and Development
基金 浙江省海洋生物技术产业科技创新团队项目(2012R10029-02) 宁波市海洋藻类资源高效开发利用创新团队项目(2011B81007) 宁波大学引进人才启动基金项目(RCL2011718) 宁波大学学科项目(XKL11D2103 XKC11002) 宁波大学创新性开放实验建设项目(Cxxkf-201226)
关键词 交替假单胞菌 结构鉴定 辅酶Q2 抗肿瘤活性 Pseudoalteromonas structure elucidation eoenzyme Q2 antitumor activity
  • 相关文献

参考文献16

  • 1Gauthier G, Gauthier M, Christen R. Phylogenetie analysis of the genera Alteromonas, Shewanella, and MoriteUa using genes coding for small-subunit rRNA sequences and divisionof the genus Aheromonas into two genera, Aheromonas (e- mended) and Pseudoaheromonas gen. nov. , and proposal of twelve new species combinations. Int J Syst Bacteriol, 1995, 45:755-761.
  • 2Bowman JP. Bioactive compound synthetic capacity and eco- logical significance of marine bacterial genus pseudoahero- monas. Mar Drugs,2007,5:220-241.
  • 3Kalinovskaya NI, Ivanova EP, Alexeeva YV, et al. Low-mo- lecular-weight, biologically active compounds from marine Pseudoalteromonas species. Curt Microbiol, 2004, 48: 441- 446.
  • 4Feher D, Barlow R, Mcatee J, et al. Highly brominated anti- microbial metabolites from a marine Pseudoaheromonas sp. J Nat Prod,2010,73 : 1963-1966.
  • 5Egan S, James S, Holmstrom C, et al. Correlation between pigmentation and antifouling compounds produced by Pseud- oaheromonas tunicata. Environ Microbiol ,2002 , 4 :433-442.
  • 6Isnansetyo A, Kamei Y. MC21-A, a bactericidal antibiotic produced by a new marine bacterium, Pseudoaheromonas phenolica sp. nov. O-BC30 ( T), against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother, 2003, 47:480-488.
  • 7Pinkerton DM, Banwell MG, Garson M J, et al. Antimicrobial and cytotoxic activities of synthetically derived tambjamines C and E -J,BE-18591 ,and a related alkaloid from the ma- rine bacterium Pseudoaheromonas tunicata. Chem Biodivers, 2010,7 : 1311-1324.
  • 8Muldoon J, Perepelov AV, Shashkov AS, et al. Structure of an acidic polysaccharide from the marine bacterium Pseudoaher-omonas flavipulchra NCIMB 2033 (T). Carbohydr Res ,2003, 338:459-462.
  • 9Rungpmm W,Siwu ERO,Lambert LK,et al. Cyclic tetrapep- tides from marine bacteria associated with the seaweed Digi- nea sp. and the sponge Halisarca ectofibrosa. Tetrahedron, 2008,64:3147-3152.
  • 10Kanoh K, Kamino K, Leleo G, et al. Pseudoaherobactin A and B, new sidemphores excreted by marine bacterium Pseud- oalteromonas sp. KP20-4. J Antibiot (Tokyo) ,2003,56:871- 875.

二级参考文献15

  • 1[1]Littarru G P. Energy and defense:facts and perspectives on coenzyme Q10 in biology and medicine[J]. Casa Editrice Scientifica Intemazionale, 1994:1~91.
  • 2[2]Kelly G S. Sport nutrition:a review of selected nutritional supplements for endurance athlets[J]. Alt Med Rev, 1997, 2: 282~ 295.
  • 3[3]Lockwood K, Mosegarard S, Wu Zu-fu. Apparent partial remission of breast cancer in high risk[J]. Mol Aspects Med, 1994,(15) :231~240.
  • 4[4]Folkers K, Osterborg A, Wu Zu-fu. Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer[J]. Biochem Biophys Res Commun, 1997,234:296~299.
  • 5[5]Folkers K, Wolaniuk A. Research on coenzyme Q10 in clinical medcine and in immunomodulation[J]. Drug Und Exper Clin Res, 1985 ,11: 539~ 545 .
  • 6[6]Mellors A, Tappel A L. The inhibition of mitochondrial peroxidation by ubiquinone and ubiquinol[J]. J Biol Chem, 1966,241: 4353 ~ 4356.
  • 7[7]Gaby A R. The role of coenzyme Q10 in clinical medicine:part. Cardiovacular disease,hypertension, diabetes mellitus and infertility[J]. Alt Med Rev, 1996,1:168~175.
  • 8[8]Littarru G P, Ho L, Folkers K. Deficiency of Coenzyme Q10 in human heart disease[J]. In:Internat J Vit Nutr Res 1972,42 (2) :291 ;42(3) :413.
  • 9[9]Langsjoen Per H, Vadhanavikit S Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10 [J]. In:Proc Natl Acad of Sci, U S A. 1985 , 82 : 4240 ~ 4244 .
  • 10[10]Judy W V, Hall JH, Toth P D, et al. Folkers K.Double blind-double crossover study of coenzyme Q10 in heart failure[A]. In:Folkers K, Yamamura Y. (eds) Biomedical and clinical aspects of coenzyme Q10 [C], Elsevier, Amster dam, 1986,5:315 ~323.

共引文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部